Cadila Healthcare is currently trading at Rs. 429.75, up by 9.75 points or 2.32% from its previous closing of Rs. 420.00 on the BSE.
The scrip opened at Rs. 418.50 and has touched a high and low of Rs. 434.30 and Rs. 418.50 respectively. So far 161776 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 329.95 on 26-Dec-2016.
Last one week high and low of the scrip stood at Rs. 434.30 and Rs. 401.75 respectively. The current market cap of the company is Rs. 44020.93 crore.
The promoters holding in the company stood at 74.79%, while institutions and non-institutions held 17.28% and 7.93% respectively.
Cadila Healthcare’s wholly owned subsidiary -- Zydus Pharmaceuticals (USA) has received final approval from the United States Food & Drug Administration (USFDA) to market Nifedipine Extended-Release Tablets USP in strengths of 30 mg, 60 mg and 90 mg. The drug is used to treat hypertension (high blood pressure) and angina (chest pain). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |